Loading…
← CockpitCompetitor Analysis › QDEL QuidelOrtho CorporationOpen in the cockpit ↗

QuidelOrtho CorporationQDELCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum laggard 14
Mkt cap
$657M
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$31.6M
20-day average traded
Fwd P/E
10.7×
forward earnings
ROIC−WACC
-7.2 pp
WACC 6.2%
Hurdle
n/a
no reverse DCF
Next earnings
91 days
17 Feb 2027
Close · USD$9.57
1D-3.0%
1W-19.6%
1M-32.6%
3M-35.6%
6M-19.6%
YTD-66.5%
1Y-54.6%
ATR %11.9%
Beta2.55
52w lowhigh73.1% off high

What QuidelOrtho does

Employees: 6,500

QuidelOrtho at a glance

Size QuidelOrtho (QDEL) is a United States Health Care company (Medical Specialties) with a market value of $657M, the 2499th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.57 on 18 Nov 2026.

Performance Over six months the shares fell 19.6%, against -9.3% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue fell 4.6% over the last twelve months (peer median +17.0%); the operating margin is -2.4% (peer median 13.7%).

Valuation It trades at 10.7× forward earnings against a peer median of 27.9× (3rd cheapest of 17).

Capital Return on invested capital runs 7.2 points below its cost of capital (6.2% WACC).

Short interest Short interest is 21.1% of the free float (30 Oct 2026).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026Peer median 92QDEL 77
Six months, rebased to 100: QuidelOrtho against the median of its 20 peers (local-currency closes).

QuidelOrtho financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.59B$2.73B$2.79B$2.99B$3.26B
Revenue growth—-2%-7%-8%—
Gross profit$959M$1.08B$1.09B$1.28B$1.80B
EBITDA$399M$494M$502M$704M$1.26B
Net income-$369M-$1.13B-$2.05B-$10.1M$549M
Free cash flow-$118M-$83.0M-$112M$70.9M$744M
Capital expenditure$126M$188M$195M$209M$141M
Total debt$3.12B$2.83B$2.68B$2.61B$2.85B

Quarterly statements and history in the cockpit →

QuidelOrtho competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%SNT30032617890028761858DCTH49100068838930123415017575688410XVIVONANMEDISGHT301122QDEL6-month return →1-month return →
Up and to the right = strong over both horizons. QuidelOrtho is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×200×SNT30032617890028761858DCTH68838968808515017575300622NAN301122QDELRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. QuidelOrtho is the large dot.

QuidelOrtho competitors and peer comparison

How QuidelOrtho compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

QuidelOrtho against its 20 peers (data as of 18 Nov 2026)
MeasureQDELPeer medianRank in peer set
1-month return-32.6%-1.9%2nd lowest of 21
6-month return-19.6%-9.3%8th lowest of 21
Distance from 52-week high-73.1%-29.3%lowest of 21
Revenue growth (TTM)-4.6%+17.0%4th lowest of 21
Operating margin-2.4%13.7%3rd lowest of 21
Forward P/E10.7×27.9×3rd cheapest of 17
ROIC minus cost of capital-7.2 pp+4.1 pp3rd lowest of 21
EV / EBITDA9.0×14.9×3rd cheapest of 10
Net debt / EBITDA7.4×-1.0×most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
QuidelOrtho QDELUnited States$657M-20%-5%-2%10.7×n/an/a
Synektik SNT.WAPoland$662M+10%+32%24%13.8×0.2%+47.5%
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%26.0×6.6%-1.9%
AK Medical 1789.HKHong Kong$642M-23%+16%26%10.5×-11.5%+6.7%
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%39.0×10.1%+14.2%
Beijing Chunlizhengda Medical Instruments 1858.HKHong Kong$631M-28%-9%31%8.5×-9.5%+1.5%
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%n/a-2.6%+18.8%
Delcath Systems DCTHUnited States$685M+75%+38%5%358.9×33.4%+120.2%
Livsmed 491000.KSSouth Korea$687M-47%+89%-77%n/an/an/a
Shenzhen Lifotronic Technology 688389.SSChina$692M-14%+14%13%29.9×11.6%+13.3%
Shanghai Sanyou Medical 688085.SSChina$692M-23%+15%4%50.0×29.0%+6.8%
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$697M+148%-14%3%n/a31.8%-0.6%
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%15.9×-3.3%+23.5%
Japan Lifeline 7575.TJapan$703M+34%+6%19%14.5×-9.5%+2.9%
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%23.5×16.2%+25.9%
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%53.1×35.9%+35.2%
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%22.8×-3.4%+15.7%
Nanosonics NAN.AXAustralia$599M-4%+3%7%98.6×35.3%+6.7%
Medistim MEDI.OLNorway$599M+32%+19%29%31.8×-1.2%+14.5%
Sight Sciences SGHTUnited States$599M+122%+16%-30%n/an/an/a
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a

Questions

Which companies are QuidelOrtho's closest peers?
The cockpit's peer set: Synektik (SNT.WA), Shanghai Kinetic Medical (300326.SZ), AK Medical (1789.HK), Shenzhen Sunnypol Optoelectornics (002876.SZ), Beijing Chunlizhengda Medical Instruments (1858.HK), SunMax Biotechnology (4728.TWO), Delcath Systems (DCTH), Livsmed (491000.KS).
Is QuidelOrtho expensive compared with its peers?
On forward p/e it trades at 10.7× against a peer median of 27.9×, 3rd cheapest of 17 in its peer set.
How has QuidelOrtho stock performed?
Over six months to 18 Nov 2026 the shares returned -19.6% against -9.3% for the median peer; over one year -54.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.